Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Naloxone is a World Health Organization (WHO)-listed essential medicine and is the first choice for treating the respiratory depression of opioids, also by lay-people witnessing an opioid overdose. Naloxone acts by competitive displacement of opioid agonists at the μ-opioid receptor (MOR). Its effect depends on pharmacological characteristics of the opioid agonist, such as dissociation rate from the MOR receptor and constitution of the victim. Aim of treatment is a balancing act between restoration of respiration (not consciousness) and avoidance of withdrawal, achieved by titration to response after initial doses of 0.4–2 mg. Naloxone is rapidly eliminated [half-life ( t 1/2 ) 60–120 min] due to high clearance. Metabolites are inactive. Major routes for administration are intravenous, intramuscular, and intranasal, the latter primarily for take-home naloxone. Nasal bioavailability is about 50%. Nasal uptake [mean time to maximum concentration ( T max ) 15–30 min] is likely slower than intramuscular, as reversal of respiration lag behind intramuscular naloxone in overdose victims. The intraindividual, interindividual and between-study variability in pharmacokinetics in volunteers are large. Variability in the target population is unknown. The duration of action of 1 mg intravenous (IV) is 2 h, possibly longer by intramuscular and intranasal administration. Initial parenteral doses of 0.4–0.8 mg are usually sufficient to restore breathing after heroin overdose. Fentanyl overdoses likely require higher doses of naloxone. Controlled clinical trials are feasible in opioid overdose but are absent in cohorts with synthetic opioids. Modeling studies provide valuable insight in pharmacotherapy but cannot replace clinical trials. Laypeople should always have access to at least two dose kits for their interim intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Time course (left: 0–240 min, right: 0–60 min) of plasma concentrations of intravenous and intramuscular naloxone (0.4 mg) and concentrated intranasal formulations of 1, 2, and 4 mg naloxone. Note the initial closeness of serum concentrations of the regulatory golden standard 0.4 mg intramuscular dose and the 2 mg intranasal dose. Note also that plasma concentrations after 2 mg intranasal naloxone surpass that of 0.4 mg intramuscular naloxone after 6 min and stay above that of intramuscular for the remaining 120 min. Also, note the dramatic overshoot by the 4 mg dose compared with the 0.4 mg intramuscular dose. Redrawn from McDonald et al. [83] with permission](https://figures.cochat.ai/paper-figures/af98393d605c4f64b63e2642619cc2eb/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-2.jpg)
![Fig. 3 Dose–concentration linearity for maximum serum concentration (Tmax) and area under the curve (AUC) after nasal spraying of 0.8–2.0 mg of concentrated nasal naloxone formulations in healthy volunteers (compiled from two different studies [48, 62] with the same formulation). This linearity is the scientific basis for a two-dose administration by laypeople in take-home naloxone (THN)](https://figures.cochat.ai/paper-figures/8d8ad05c57804a1cb930ebc329e3741c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-3.jpg)
![Fig. 4 Inter- and intraindividual variability of the absolute bioavailability of intranasal naloxone [AUC(IN)/AUC(IV) × DOSE(IV)/DOSE(IN)] based on AUC0−inf in 22 healthy volunteers. Not only does the absolute nasal bioavailability vary from about 20% to almost 100% between individuals but also is usually reproduced in an individual. Similar findings were observed for the relative intranasal to intramuscular bioavailability in the same subjects [19]](https://figures.cochat.ai/paper-figures/60c0086d84d04aa1a3816c462545ec6c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-4.jpg)
![Fig. 5 Time course of pupil diameter in healthy volunteers exposed to remifentanil and naloxone [n = 12, mean (95% confidence interval)]. Remifentanil was started at t = −12 min and stopped at t = 90 min (orange, horizontal line). Miosis was rapidly reversed by a naloxone bolus of 1 mg intravenously given at t = 0. The blue broken line is the regression line [f(x) = − 0.0292x + 6.9924)] and is based on the period 19–89 min. It crosses the nadir baseline (black dotted line) at 118 min. The blood concentration of naloxone at this point was 0.5 ng/ml, which is the minimum effective concentration of naloxone in steady state. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/578f4a8864ce412a8c8ee73b51100f6f/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-5.jpg)
![Fig. 6 Hysteresis plot of pupil diameter and naloxone concentration during a remifentanil infusion with stable blood concentrations (see legend for Fig. 5). The red line represents arterial samples, and the blue line represent venous samples. The direction of time is illustrated by the arrow. This finding allows for the use of venous concentrations in PK/PD modeling. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/b220aa8ae742457b8a62ffa4a663d065/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-6.jpg)
![Fig. 7 Simulated time courses of mean naloxone concentrations (lines) and standard deviations as shaded areas: 0.8 mg intramuscular (dark gray), 0.4 mg intramuscular (light gray), and 1.4 mg intranasal (blue). Time of administration of injected naloxone is t = 0 min. A Intranasal 1.4 mg administered 10 min prior to injected naloxone (0.4 and 0.8 mg). B Simulation of the shortest time (2.25 min) beneficial to administer the intranasal spray, rather than wait for naloxone to be injected by medical personnel. C Simulation of 1.4 mg intranasal naloxone when intramuscular 0.4 mg naloxone is injected to a patient 10 min before the intranasal dose. Redrawn from Skulberg et al. [77]](https://figures.cochat.ai/paper-figures/e36c40238a254694b601924d47af563e/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-7.jpg)
![Fig. 8 Simulated concentration–time profiles of plasma naloxone after various common clinical dosing schemes in opioid overdose. A pharmacokinetic model based on our own data and 1000 simulations were used (Anesthesiology, manuscript in review) [108]. Two intravenous (0.4 and 2 mg, shown in gray and black, respectively) and three intramuscular doses (0.4, 0.8, and 2.0 mg, shown in light blue, yellow and blue, respectively) were simulated using the final pharmacokinetic model. The lower dotted line suggests the duration of action, represented by an experimentally determined minimum effective concentration of 0.5 ng/ml [76] and the upper dotted line suggests an increased risk of withdrawal, represented by the Cmax (3.2 ng/ml) and 0.8 mg intramuscular dose [18, 109]](https://figures.cochat.ai/paper-figures/85677e99c40a46719425a695c6f3385b/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-8.jpg)
![Fig. 9 Simulated plasma concentration profiles after single bolus doses (0.9, 1.4, 2.0, or 4.0 mg) of intranasal naloxone, alone or with remifentanil dosing (A and B, respectively) using a pharmacokinetic model based on our own data (Anesthesiology, manuscript in review) [108]. Plasma concentration–time course of the regulatory golden standard, an intramuscular 0.4 mg bolus dose, is shown in blue](https://figures.cochat.ai/paper-figures/c080496a8e7b45d281e0d6f2b31e4458/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-9.jpg)
![Fig. 10 A randomized, double-blinded comparison of naloxone given intramuscularly (0.8 mg, blue) or intranasally (1.4 mg, brown) by the ambulance service in opioid overdose (n = 201) Shaded areas represent 95% confidence interval. Kaplan–Meier plot showing the probability of not having reached satisfactory respiration (10 breaths/min). Curves are similar until 3 min, and the restoring of respiration is 2.3 min slower after the intranasal dose at 10 min. In real life, this difference is probably smaller, as intranasal administration is likely faster to complete than intramuscular. These intoxications were also more serious than those in an unselected material in the same catchment area [110]. Redrawn from Skulberg et al. [73]](https://figures.cochat.ai/paper-figures/dac41243484b4e5ab028ddedcda09040/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interindividual tolerance to different opioids varies greatly from opioid-naive patients to patients who use opioids regularly.”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nitazene’s high potency and activation at the mu opioid receptor allows for naloxone reversal through competitive antagonism at this exact receptor [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early naloxone administration remains critical because reversal of opioid respiratory depression reduces the mortality risk of these drugs [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is highlighted for morphine, as its serum concentrations were significantly higher in patients receiving intravenous morphine for cancer-related pain than in all morphine-positive post-mortem cases in another study [14,47].”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Mould, D., & Upton, R. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.14 · Cited by 897
Management of Opioid Analgesic Overdose
Boyer, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1202561 · Cited by 605
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 544
EEG Quantitation of Narcotic Effect: The Comparative Pharmacodynamics of Fentanyl and Alfentanil
Scott, J. C., Ponganis, K. V., & Stanski, D. R. (1985) · Anesthesiology · doi:10.1097/00000542-198503000-00005 · Cited by 492
McDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Self-citationNaloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action
Ngai, S. H., Berkowitz, B. A., Yang, J. C., Hempstead, J., & Spector, S. (1976) · Anesthesiology · doi:10.1097/00000542-197605000-00008 · Cited by 287
Nasal administration of opioids for pain management in adults
Dale, O., Hjortkjær, R., & Kharasch, E. D. (2002) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2002.460702.x · Cited by 270
Self-citation
Research works printed but not linked: 6
- Garfield E The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone Essay Inf Sci 1983 6 121 130
- Blumberg H Dayton HB George M Rapaport DN N-allylnoroxynorphone; a potent narcotic antagonist Fedn Proc Fedn Am Soc 1961 20 311
- Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer. Accessed Oct 26 2022.
- World Health Organization, Management of Substance Abuse Team Community management of opioid overdose 2014 Geneva World Health Organization
- Lemen PM Garrett DP Thompson E Aho M Vasquez C Park JN High-dose naloxone formulations are not as essential as we thought medRxiv 2023 6 63 PMC11089786 38741224
- World Health Organization WHO guidelines approved by the guidelines. Review committee community management of opioid overdose 2014 Geneva World Health Organization
Cited by
Nitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Self-citationA call for compassionate opioid overdose response
Russell, E., Hawk, M., Neale, J., Bennett, A. S., Davis, C., Hill, L. G., Winograd, R., Kestner, L., Lieberman, A., Bell, A., et al. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104587 · Cited by 28
Stevens, A., Keemink, J. R., Shirley‐Beavan, S., Khadjesari, Z., Artenie, A. A., Vickerman, P. T., Southwell, M., & Shorter, G. W. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13908 · Cited by 27
Synthetic opioids have disrupted conventional wisdom for treating opioid overdose
Skolnick, P., Paavola, J., & Heidbreder, C. A. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100268 · Cited by 19
Naloxone dosing in the era of synthetic opioids: Applying the Goldilocks principle
Utrilla, M. G., Chesney, E., Neale, J., Metrebian, N., Kalk, N. J., Skulberg, A. K., Dietze, P., Smith, M. P., & Strang, J. (2025) · Addiction · doi:10.1111/add.70060 · Cited by 16
Self-citationSinclair, J., Kalk, N. J., Kaar, S. J., Agabio, R., Arunogiri, S., Bisaga, A. M., Chesney, E., Daly, C., Dewhurst, J., Freeman, T. P., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251399593 · Cited by 16
Gold, M. S., Milas, B. L., Cutchins, C., WALSH, S. L., Piotrowski, J., & Boyer, E. W. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00648-5 · Cited by 9
Fentanyl Disrupts Vagal Control of Airway Tone to Induce Transient Obstruction
Parks, R. R., Andersen, M. J., Hatfield, M. L., & Burgraff, N. J. (2025) · Acta Physiologica · doi:10.1111/apha.70119 · Cited by 8
Fentanyl–Antibody Interaction as a Novel Strategy against Opiates and Opioids Abuse
Ribaudo, G., Taccani, A. A., & Gianoncelli, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02860 · Cited by 8
Neale, J., Cassidy, J., Cosgrove, S., Carter, B., Dascal, T., Mackie, C. J., Metrebian, N., & Strang, J. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01203-1 · Cited by 7
Self-citationDasgupta, N., Bell, A., Visnich, M., Doe-Simkins, M., Wheeler, E., Sibley, A. L., Nocera, M., Seitz, A. E., Chang, D., Barlow, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315026 · Cited by 8
Harrison, E., Brant, K., Strong-Jones, S., Skogseth, E. M., Latkin, C. A., & Jones, A. A. (2024) · Psychology of Addictive Behaviors · doi:10.1037/adb0001021 · Cited by 7
Precipitated Withdrawal Induced by Prehospital Naloxone Administration
Vandergrift, L. A., Rice, A. D., Primeau, K., Gaither, J. B., Munn, R. D., Hannan, P. L., Knotts, M., Hollen, A., Stevens, B., Lara, J., et al. (2025) · Prehospital Emergency Care · doi:10.1080/10903127.2024.2449505 · Cited by 5
Assessing the efficacy of nanoparticles in reversing opioid poisoning and preventing renarcotization
Manes, A., Sran, J., & Bach, H. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2463864 · Cited by 5
Karabulut, B. Ö., & Akgün, M. (2026) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-025-00129-y · Cited by 6
Malfatti, M. A., Enright, H. A., McCloy, S. A., Ubick, E. A., Kuhn, E. A., Subramanian, A., Lao, V., Lam, D., Be, N. A., Hok, S., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.4c00682 · Cited by 4
Intranasal overdose reversal formulations: a rapid review of available agents
Bernosky‐Smith, K. A., Painter, O. B., Butler, S., Patel, D., Clemency, B. M., & Lynch, J. J. (2025) · Pain Management · doi:10.1080/17581869.2025.2461445 · Cited by 3
An impact evaluation of the Scottish take-home naloxone programme
Adams, T. J., Teck, J. T. W., Baldacchino, A., & Forget, P. (2025) · Health Policy and Technology · doi:10.1016/j.hlpt.2025.101072 · Cited by 3
Withdrawal-Induced Delirium in Opioid Dependence: A Systematic Review
Świderski, N., Rodek, P., & Kucia, K. A. (2025) · Brain Sciences · doi:10.3390/brainsci15101118 · Cited by 2
Digranes, N., Pettersson, E., Lervik, A., Bogen, I. L., Andersen, J. M., Nordgreen, J., & Haga, H. A. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112969 · Cited by 2
Reversal of a synthetic opioid overdose: Insights from a validated translational model
Laffont, C. M., Purohit, P. G., de la Peña, A., & Skolnick, P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110546 · Cited by 3
Jaskuła, K., Nawrocka, A., Poznański, P., Stachowicz, A., Łazarczyk, M., Sacharczuk, M., Gaciong, Z. A., & Skiba, D. S. (2025) · Biomedicines · doi:10.3390/biomedicines13081802 · Cited by 2
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond Fentanyl
Dow, L. F., Abisogun, A. A., Berida, T. I., Krishnan, S. C., Rathnayake, U., & Lindsley, C. W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00696 · Cited by 3
Historical perspectives and emerging trends in fentanyl use: Part 2 – overdose and misuse
Stoeva, S., Radeva-Ilieva, M. P., Hvarchanova, N., Dragomanova, S., Kehayova, G. K., Dimitrova, S., Petrova, M., Zlateva, S., & Marinov, P. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e149215 · Cited by 3
Navin, M. C., Fink, L. R., & Rieder, T. N. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104945 · Cited by 1
Bless, P., Blaser, D., Castelain, T., Pugnale, S., Ribordy, V., & Guéchi, Y. (2025) · Toxics · doi:10.3390/toxics13121034 · Cited by 2
Kashindye, R. C., Yadav, D., & Yadav, R. (2026) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2026.103069 · Cited by 2
Exploring wanting and liking during positive human-animal interactions
Truong, S., Schmitt, O., Buisman‐Pijlman, F. T. A., Oczak, M., & Rault, J. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07015-w · Cited by 1
Beyond the Usual: Novel Therapeutic Roles for Established Antidotes
Koppen, A., Dijkman, M. A., Visser, C. C., & de Lange, D. W. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001433 · Cited by 1
Patel, A., Dabke, A., & Sawant, K. K. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10322-y · Cited by 1
Raffa, R. B., Vortsman, E., Pergolizzi, J. V., Casazza, K., & King, M. W. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6010011 · Cited by 1
Brown, D. G., Sultana, T. A., Faustino, P. J., & Shakleya, D. M. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104215 · Cited by 1
Roj, A. R., Siddh, S., Sharma, H. C., Foujdar, D., Mishra, E., Kumar, S., Vartika, K. M., Pundir, M., Mishra, G., Saini, S., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1759745 · Cited by 1
Youn, D. H., Jung, H., Lee, J., Pak, S., Han, S. W., Kim, J.-T., Song, K., Choi, H. R., Han, G. S., Kwon, Y.-S., et al. (2026) · Life · doi:10.3390/life16030480 · Cited by 1
Experimental assessment of intravenous lipid emulsion in the management of acute fentanyl poisoning
Yarabanova, I., Драгоманова, С., Stoeva-Grigorova, S., Hvarchanova, N., Kehayova, G. K., Radeva-Ilieva, M. P., Stoychev, E., Димитрова, С., Zlateva, S., & Маринов, П. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e189383 · Cited by 1
Würsten, M., Meyer‐Massetti, C., Leuppi-Taegtmeyer, A., & Goetschi, A. N. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s607184 · Cited by 1
Fentanyl Compromises Lower‐Airway Mechanics and Naloxone Triggers a Transient Mechanical Overshoot
Parks, R. R., Andersen, M. J., Hatfield, M. L., Johnson, M. M., & Burgraff, N. J. (2026) · Acta Physiologica · doi:10.1111/apha.70253 · Cited by 1
Lewis, M., & Walentiny, D. M. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111106 · Cited by 1
Srivastava, S. K. (2024) · Materials Advances · doi:10.1039/d3ma00824j · Cited by 1
Venuso, L., Ricciardi, F., Prete, A. D., Virgolesi, M., Pucciarelli, G., Langella, L., & Rea, T. (2025) · Emergency Care Journal · doi:10.4081/ecj.2025.13110 · Cited by 1
Wong, J. S. H., Lau, A., & Azar, P. (2025) · Addiction · doi:10.1111/add.70144 · Cited by 1
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01525-0
Opioid Kullanım Bozukluğu ve Farmakolojik Tedavisinde Kullanılan İlaçlar
Ertuğ, P., & Ecemiş, S. (2024) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1492043
Загроза мілітаризації синтетичних опіоїдів і підходи до розробки антидотів та засобів захисту
Проданчук, М. Г., Kurdil, N. V., Zinovieva, M. L., Aleynov, P., & Mykhaylov, V. S. (2025) · Ukrainian Journal of Military Medicine · doi:10.46847/ujmm.2025.1(6)-062
Changes Over Time in Naloxone Dosing and Route in Adolescent Opioid Toxicity
Sidlak, A. M., Goncalves, M., Ahmed, R., & Dhaliwal, M. (2025) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.04.006
Yacoub, O. N. A., Shen, C., Fayed, M. S., Fisher, J. E., Brooks, J., Seaquist, E. R., Kumar, A. F., Moheet, A. A., Eberly, L. E., & Coles, L. D. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70067
Wojciechowski, P., Zając, D., Górski, A., Kamysz, W., Kleczkowska, P., & Kaczyńska, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157188
Buprenorphine Rescue in Acute Opioid Toxicity: An Alternative to Naloxone Infusion
Urie, B., Stover, S., & Pueringer, R. (2025) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2025.1410071
Spadaro, A., Imperato, N. S., Scalgione, J., & Santos, C. D. (2025) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.25-00263
Nitazenes and other opioid receptor superagonists
Rychlíčková, J., & Kunová, E. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.061
Opioid overdose: evidence-based management guidelines and new antidote development
King, A., & Thanacoody, R. H. K. (2025) · Medical Research Archives · doi:10.18103/mra.v13i10.6949
Novel synthetic opioids: Pharmacologic considerations
Ragland, A. R., Boullion, J. A., Hill-Mak, J. C., Mott, K. R., Shekoohi, S., & Kaye, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26504-4.00019-3
Trauma, Cirurgia e Medicina Intensiva - Ed. X
Floss, L. O. W., Silveira, G. B. C., DIAS, G. M., BARCELLOS, A. R. D., GRESSLER, L. D. A., Calumby, T. A., Vascão, E., Freitas, G. B. L. D., Dalenogare, P. Z., & WASTOWSKI, T. M. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-311-3
Naloxona: Manejo Da Overdose E Abuso De Opioides - Perspectiva Clínica
Festa, I. V., Ruschel, R. N., Fernandes, M. F. G. M., FOGAÇA, P. F., Vianna, M. Z., Berto, B. R., Reis, J. C., BAPTISTA, F. H., Silvestri, J., Schmitt, M. B., et al. (2025) · Editora Pasteur eBooks · doi:10.59290/2455120811
Chen, X.-X., Han, X.-F., & Chu, Y. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i1.115201
Correia, G. O. N. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Synthesis and Analgesic Activity of New α-Pinene-Based Cineol-Like Methanopyrano[4,3-b]pyrans
Ilyina, I. V., Pavlova, A. V., Filippova, A. Y., Patrusheva, O. S., Volcho, K. P., Sidorenko, A. Y., Agabekov, V. E., Толстикова, Т. Г., & Salakhutdinov, N. F. (2026) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606234
ACUTE RESPIRATORY FAILURE DUE TO METHADONE POISONING
Шилин, Д. С., FEDOROVTSEV, D. V., Kazakov, R. M., & Шаповалов, К. Г. (2026) · Zabajkalʹskij medicinskij vestnik · doi:10.52485/19986173_2025_4_173
CURRENT AND EMERGING PHARMACOTHERAPIES IN OPIOID USE DISORDER: A NARRATIVE REVIEW
Mubashir Raza, J. K. S. (2026) · Review journal of neurological & medical sciences review. · doi:10.5281/zenodo.18781137
Loría-Castellanos, J., Cerón-Apipilhuasco, A., & Meneses, D. M. (2025) · Archivos de Medicina de Urgencia de México · doi:10.35366/122680
Esmaylpur, Q., Korani, Z. K., Agah, M., Azizi, E., Rajabzadeh, M., Sarabi, H. R., & Fekri, K. (2025) · Biomedical Research Bulletin · doi:10.34172/biomedrb.9070
Distributing intranasal naloxone in rural communities: Implementation of a novel approach
Rose, G. L., Crosswhite, S., Peck, K. R., Heil, S. H., & Sigmon, S. C. (2026) · Journal of Prevention and Health Promotion · doi:10.1177/26320770261434033
Li, E., Kale, B. S., Silte, A. A., Lyu, R., Upadhyay, N., Neel, L. T., Reda, A., Wang, H., Dewey, W. L., Pagare, P. P., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00836
Outcompeting opioid-induced respiratory depression
Andersen, M. J., Parks, R. R., Langer, T. M., III, & Burgraff, N. J. (2026) · Journal of Thoracic Disease · doi:10.21037/jtd-2026-1-0221
Repella, M., & Gannon, K. (2026) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.70114
Population Pharmacokinetics of Intranasal Amiloride in Healthy Volunteers
Jain, M., Kumar, S., Battaglia, M., Davies, S., Rower, J. E., Reilly, C. A., & Yellepeddi, V. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-01011-3
More than an opioid: dissociable analgesic and behavioral effects of kratom in planarians
Brasfield, L. S., Kelly, J. R., Daugherty, H., & Gilmer, M. A. (2026) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000885
Molecular pharmacology and structural insights of naloxone: a comprehensive review
Reddyrajula, R., Veeramachaneni, Y., Gadiraju, V., Etikyala, U., & Veeranki, D. (2026) · Discover Molecules · doi:10.1007/s44345-026-00060-0
Cassie, D., Warnock, B., Akhtar, F. N., McCloskey, D., & Wyatt, D. J. (2026) · Clinical and Translational Science · doi:10.1111/cts.70640
Rehn, J., Andréll, C., Hansson, J., Troberg, K., Isendahl, P., Bråbäck, M., Svensson, L., Byrsell, F., Claesson, A., & Håkansson, A. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115692
Kehayova, G. K., Yarabanova, I., Stoeva, S., Hvarchanova, N., Radeva-Ilieva, M. P., Stoychev, E., Dragomanova, S., Димитрова, С., Zlateva, S., & Маринов, П. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135983
Gholami, N., Skulberg, A. K., Farnaghi, F., Zamani, N., Kolahi, A., McDonald, R., & Hassanian‐Moghaddam, H. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113259
Prada, L. R., Lester, P. R., Runjaic, S., de la Guardia, M. E. B., & Miller, H. L. (2026) · Journal for Healthcare Quality · doi:10.1097/jhq.0000000000000534
Alsayed, Y. M., Wagdy, M., Janazreh, Y. J., Abdelmegid, A., Elzain, W., Heikal, Y., Jawad, H. A., & Hameed, A. A. Z. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02519-0
PRIKLAUSOMYBĖ NUO FENTANILIO IR PERDOZAVIMAS: KLINIKA, DIAGNOSTIKA, GYDYMAS
Simanavičiūtė, G., Radavičiūtė, A., Janusauskas, M., & Genienė, G. (2026) · Sveikatos mokslai · doi:10.35988/sm-hs.2026.203
Edema polmonare nell'intossicazione acuta fatale da oppioidi: il ruolo della acquaporina 1
Giovannini, E. (2026) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.48676/unibo/amsdottorato/12668
Sultana, T. A., Al-Ghabeish, M., Chopski, S. G., Walenga, R. L., Shakleya, D. M., Newman, B. W., Ashraf, M., & Zidan, A. S. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04153-w
Voronkov, M. V., Milevich, G., & Abernethy, J. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105002
Allosteric regulation in μ-opioid receptor homodimerization: a molecular dynamics simulation study
Ibarguren, M. P. (2026) · UCrea (University of Cantabria)
Opioid Addiction and Management with Naloxone: Emerging Concepts in Clinical Care
Jones, C., Cooper, H. D., Neuchat, E. E., WITT, A. B. D., Hirsch, J. D., Shekoohi, S., & Kaye, A. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_9
Claridge, E. (2026) · The Atrium (University of Guelph)
Opioid overdose detection and reversal with closed-loop systems
Angelone, L. M., & Koustova, E. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00492-w · Cited by 1
Saphier, S., Wenger, A., Pevzner, A., Yeffet, D., Smolkin, B., Karton-Lifshin, N., Elias, S., Eichen, Y., Parvari, G., Katalan, S., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00324
McCormick, N. P., Flores, C. S., Aycock, O., Patterson, V., Mengel, F., Woods, S., Blythe, E., Radzinski, O., Holland, M. B., Sanders, M., et al. (2026) · Pharmacy · doi:10.3390/pharmacy14060137
Bascombe, K. M., Patregnani, M., Gubac, D., Authelet, K., Hern, G., Anderson, E. S., Simpson, N. S., Carroll, G. G., & Herring, A. A. (2026) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2026.09.011
PEMODELAN MOLEKUL MITRAGYNINE SEBAGAI AGONIS PARSIAL PADA RESEPTOR OPIOID KELAS MU
Istyastono, E. P. (2026) · Prosiding Seminar Nasional Universitas Ma Chung
Lima, L. S., Pereira, M. E., Souza, J. V., de Andrade, D., Voigt, C. R., Bassani, J. B. G., Prando, C., Matos, C., Joaquim, J. J., & Oliveira, C. S. (2026) · Jornal de Pediatria · doi:10.1016/j.jped.2026.101628
Greb, I., & Hillus, J. (2026) · Notarzt · doi:10.1055/a-2784-7241
Exploring the addictive potential of α-methylfentanyl and acetyl-α-methylfentanyl in animal models
deli, X., kaixi, L., xuesong, S., simeng, Z., jingzhi, R., lixin, K., Luo, X., Xu, P., yuanyuan, C., & Peng, X. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07185-7
Seltzer, J. A., Alfieri, T. J., Nene, R. V., Castillo, E. M., Smurzynski, M., Zhao, X., Wang, S., Zhao, Y., & Tomaszewski, C. (2026) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2026.10.003
Hossain, J. A., Taft, D. R., Sweeney, K., Khairuzzaman, A., & Bellantone, R. A. (2026) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-026-10070-7
Utrilla, M. G., Baker, A., Chesney, E., Lee, K., Emsley, R., & Strang, J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0347370
Self-citationda Silva, T. R., Machado, K. L. B., Carvalho, I. M. M., de Sousa, D. C., Campos, F. D. D. M., da Silva, G. O., de Oliveira, G. A. M. D. L., de Sousa, R. P., Silva, F. M. D. S., do Amaral, F. P. D. M., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122602
Metadata
- Authors
- Saari, T. I., Strang, J., & Dale, O.
- Affiliations
- University of Turku (FI)
- King's College London (GB)
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Dale, Ola
- Venue
- Clinical Pharmacokinetics
- Published
- 2024-03-14
- Volume
- 63
- Issue
- 4
- Pages
- 397-422
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC11052794
- OpenAlex
- W4392796714
- Cited by
- 77
- References
- 154
- Citations by year
- 2026: 41 · 2025: 29 · 2024: 7
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UTUPub (University of Turku) (submittedVersion, cc-by-nc)
- Funders
- NTNU Norwegian University of Science and Technology
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- naloxone, opioid overdose, respiratory depression, mu-opioid receptor, pharmacokinetics, pharmacodynamics, intranasal administration, take-home naloxone, heroin overdose, fentanyl overdose, pharmacokinetic variability
- MeSH terms
- Administration, Intranasal, Analgesics, Opioid, Animals, Half-Life, Humans, Naloxone, Narcotic Antagonists, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.